Results 1 to 10 of about 273,945 (182)

Assessment of the Efficacy and Safety of a Dual-Wavelength Diode Laser System for the Treatment of Vulvovaginal Atrophy in Women Without a History of Breast Cancer and in Patients with a History of Breast Cancer. [PDF]

J Clin Med
Background/Objectives: Vaginal laser therapy is a promising treatment for menopausal vulvovaginal atrophy (VVA). This study evaluates the efficacy of a dual-wavelength diode laser (980 + 1470 nm) in treating VVA.
Perrini G, Actis S, Giorgi M, Accomasso F, Minella C, Fava C, Bisconte G, De Rosa G, Ferrero A, Bounous VE.   +9 more
europepmc   +4 more sources

Hormonal Approach for Postmenopausal Vulvovaginal Atrophy. [PDF]

Front Reprod Health, 2021
Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen in premenopausal women. The hypoestrogenic condition results in hormonal and anatomical changes, with
Costa APF, Sarmento ACA, Vieira-Baptista P, Eleutério J, Cobucci RN, Gonçalves AK.   +5 more
europepmc   +6 more sources

Use of Moisturizers and Lubricants for Vulvovaginal Atrophy. [PDF]

Front Reprod Health, 2021
The estrogen decrease in postmenopausal women results in functional and anatomical changes in the genitourinary tract. The most prevalent and bothersome symptoms are vaginal dryness, dyspareunia, and reduced lubrication, which can significantly affect the quality of life of these women, principally those who are sexually active.
Sarmento ACA, Kamilos MF, Costa APF, Vieira-Baptista P, Eleutério J, Gonçalves AK.   +5 more
europepmc   +6 more sources

Vulvovaginal Atrophy [PDF]

Mayo Clinic Proceedings, 2010
Vulvovaginal atrophy (VVA) is a common and underreported condition associated with decreased estrogenization of the vaginal tissue. Symptoms include dryness, irritation, soreness, and dyspareunia with urinary frequency, urgency, and urge incontinence. It can occur at any time in a woman's life cycle, although more commonly in the postmenopausal phase ...
Deborah J Rhodes, Lynne T Shuster
exaly   +5 more sources

Prevalence of urinary tract infections in women with vulvovaginal atrophy and the impact of vaginal prasterone on the rate of urinary tract infections. [PDF]

Menopause
This study suggests that intravaginal prasterone may be a good candidate for prophylaxis in postmenopausal women with urinary tract infections to reduce future urinary tract infection risk, including for women taking aromatase inhibitors and women with ...
Rubin R, Sanaee M, Yee A, Moyneur E, Dea K, Dury AY.   +5 more
europepmc   +2 more sources

Value of injection of plasma-rich platelets in the vaginal mucosa in cases with vulvovaginal atrophy: a prospective double-blinded randomized controlled study. [PDF]

BMC Womens Health
The use of Plasma-Rich Platelets (PRP) in the vaginal mucosa for vulvovaginal atrophy (VVA) symptom relief is still being studied. This trial aimed to assess the efficacy of PRP injections in alleviating VVA symptoms.
Hamid ASA, AbdAllah AM, Fathi HM, Eldin AMB, Abd El Hadi RMM.   +4 more
europepmc   +2 more sources

Assessing the Noninferiority of the Spermidine Hyaluronate Complex Relative to 17β-Estradiol Treatment in the Ovariectomized Murine Model of Vulvovaginal Atrophy. [PDF]

J Menopausal Med
Objectives Vulvovaginal atrophy (VVA) presents significant challenges in postmenopausal women. VVA is typically managed either with hormonal-estrogenic therapy or nonpharmacologically with hyaluronic acid (HA) treatments.
Ghisalberti CA, Tezze C.
europepmc   +2 more sources

Case series on the effect of ayurvedic medications in the management of symptoms of vulvovaginal atrophy in postmenopausal women. [PDF]

J Ayurveda Integr Med
This case series investigates the effectiveness of Ayurvedic treatments in managing genital symptoms of Vulvovaginal Atrophy (VVA) in postmenopausal women.
Surendran ES, Balakrishnan P, Raj LS.
europepmc   +2 more sources

Topical Spermidine Hyaluronate (Spd-HA) in Vulvovaginal Atrophy: A Preliminary Study. [PDF]

Medicina (Kaunas)
Background and Objectives: Genitourinary syndrome of menopause (GSM), previously termed vulvovaginal atrophy (VVA), is a prevalent hypoestrogenic condition characterized by genital, sexual, and urinary symptoms. Although hormonal therapies are effective,
Porcari I, Carena Maini M, Ghisalberti CA, Tezze C, Trimarchi E, Graziottin A, Bosco M, Casprini C, Garzon S, Uccella S.   +9 more
europepmc   +2 more sources

Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options. [PDF]

Medicina (Kaunas)
Vulvovaginal atrophy, characterized by the thinning of vaginal mucosa typically resulting from reduced estrogen levels, is frequently exacerbated by oncogynecologic treatments such as chemotherapy, hormonal therapy, radiotherapy, or surgery.
Narutytė R, Žukienė G, Bartkevičienė D.   +2 more
europepmc   +2 more sources